3 results
Approved WMOPending
Primary objective:To determine the pharmacokinetics of E7080 and its excretion balance in order to elucidate its metabolic profile in plasma, urine, and feces following a single oral dose of radiolabeled 14C-E7080 in patients with advanced tumors or…
Approved WMORecruiting
The objective is to determine whether etidronate can halt or attenuate disease progression in patients with Fahr*s disease or syndrome.
Approved WMORecruiting
Primary Objective To determine if 24 months of treatment with etidronate halts the progression of arterial calcification in the legs and carotid siphons. Secondary Objectives 1. To determine the effect of 24 months of treatment with etidronate on…